{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:29:50Z","timestamp":1761172190131,"version":"build-2065373602"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.semerg.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T02:03:14Z","timestamp":1627524194000},"page":"411-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vacunaci\u00f3n frente a la neumon\u00eda adquirida en la comunidad del adulto. Actualizaci\u00f3n 2021 del posicionamiento del Grupo de Neumoexpertos en Prevenci\u00f3n"],"prefix":"10.1016","volume":"47","author":[{"given":"E.","family":"Redondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Rivero-Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mascar\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Yuste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fern\u00e1ndez-Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"D\u00edaz-Maroto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Linares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2021.06.005_bib0515","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semerg.2016.07.009","article-title":"Vacunaci\u00f3n frente a la neumon\u00eda adquirida en la comunidad del adulto. Posicionamiento del Grupo de Neumoexpertos en Prevenci\u00f3n [Vaccination against community acquired pneumonia in adult patients. A position paper by Neumoexpertos en Prevenci\u00f3n]","volume":"42","author":"Redondo","year":"2016","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2021.06.005_bib0520","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.semerg.2018.09.005","volume":"44","author":"Redondo","year":"2018","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2021.06.005_bib0525","unstructured":"Medicine CfE-B. Oxford Centre for Evidence-based Medicine \u2013 Levels of Evidence (March 2009) [consultado 29 Mar 2021]. Disponible en: https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/"},{"key":"10.1016\/j.semerg.2021.06.005_bib0530","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.06.005_bib0535","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.10.2100193","article-title":"Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain January and February 2021","volume":"26","author":"Fern\u00e1ndez-Prada","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.semerg.2021.06.005_bib0540","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/d41586-021-00316-4","article-title":"Vaccines are curbing COVID: Data from Israel show drop in infections","volume":"590","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.semerg.2021.06.005_bib0545","article-title":"Decreased SARS-CoV-2 viral load following vaccination","author":"Levine-Tiefenbrun","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.semerg.2021.06.005_bib0550","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","author":"Dagan","year":"2021","journal-title":"New Eng J Med"},{"key":"10.1016\/j.semerg.2021.06.005_bib0555","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00448-7","article-title":"Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients","author":"Amit","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2021.06.005_bib0560","doi-asserted-by":"crossref","unstructured":"Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts. Disponible en: https:\/\/doi.org\/10.1101\/2021.02.05.21251139","DOI":"10.1101\/2021.02.05.21251139"},{"key":"10.1016\/j.semerg.2021.06.005_bib0565","unstructured":"Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Disponible en: https:\/\/ssrn.com\/abstract=3790399"},{"key":"10.1016\/j.semerg.2021.06.005_bib0570","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.06.005_bib0575","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2021.06.005_bib0580","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2021.06.005_bib0585","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots"},{"key":"10.1016\/j.semerg.2021.06.005_bib0590","unstructured":"Vasileiou E, Simpson CR, Robertson C, Shi T, Kerr S, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. Disponible en: https:\/\/ssrn.com\/abstract=3789264"},{"key":"10.1016\/j.semerg.2021.06.005_bib0595","doi-asserted-by":"crossref","unstructured":"Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study. Disponible en: https:\/\/ssrn.com\/abstract=3796835, o https:\/\/doi.org\/10.2139\/ssrn.3796835","DOI":"10.2139\/ssrn.3796835"},{"key":"10.1016\/j.semerg.2021.06.005_bib0600","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.fda.gov\/media\/146303\/download"},{"key":"10.1016\/j.semerg.2021.06.005_bib0605","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-covid-19-vaccine-janssen-authorisation-eu"},{"key":"10.1016\/j.semerg.2021.06.005_bib0610","unstructured":"Estrategia de vacunaci\u00f3n frente a COVID 19 en Espa\u00f1a. Actualizaci\u00f3n 3. Grupo de Trabajo T\u00e9cnico de Vacunaci\u00f3n COVID-19, de la Ponencia de Programa y Registro de Vacunaciones. 9 de febrero de 2021. Disponible en https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/covid19\/docs\/COVID-19_Actualizacion3_EstrategiaVacunacion.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0615","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0620","article-title":"Hospital incidence, in-hospital mortality and medical costs of pneumococcal disease in Spain (2008-2017): A retrospective multicentre study","author":"Darb\u00e0","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semerg.2021.06.005_bib0625","article-title":"Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era","author":"De Miguel","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0630","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1086\/591708","article-title":"Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness","volume":"198","author":"Morens","year":"2008","journal-title":"J Infect Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0635","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/irv.12398","article-title":"The frequency of influenza and bacterial coinfection: A systematic review and meta-analysis","volume":"10","author":"Klein","year":"2016","journal-title":"Influenza Other Respir Viruses."},{"key":"10.1016\/j.semerg.2021.06.005_bib0640","doi-asserted-by":"crossref","first-page":"e1001776","DOI":"10.1371\/journal.pmed.1001776","article-title":"Association between respiratory syncytial virus activity and pneumococcal disease in infants: A time series analysis of US hospitalization data","volume":"12","author":"Weinberger","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.semerg.2021.06.005_bib0645","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1471-2334-13-229","article-title":"Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States","volume":"13","author":"McGarry","year":"2013","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0650","doi-asserted-by":"crossref","first-page":"198005","DOI":"10.1016\/j.virusres.2020.198005","article-title":"Co-infection with respiratory pathogens among COVID-2019 cases","volume":"285","author":"Zhu","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.semerg.2021.06.005_bib0655","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13613-020-00736-x","article-title":"Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU","volume":"10","author":"Contou","year":"2020","journal-title":"Ann Intensive Care."},{"key":"10.1016\/j.semerg.2021.06.005_bib0660","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1002\/ppul.24916","article-title":"SARS-CoV-2 and Streptococcus pneumoniae coinfection as a cause of severe pneumonia in an infant","volume":"55","author":"Nieto-Moro","year":"2020","journal-title":"Pediatr Pulmonol."},{"key":"10.1016\/j.semerg.2021.06.005_bib0665","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.medcli.2020.05.022","article-title":"Hospital Cl\u00ednic 4H Team Pneumococcal superinfection in COVID-19 patients: A series of 5 cases","volume":"155","author":"Cucchiari","year":"2020","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.semerg.2021.06.005_bib0670","article-title":"Pneumococcal co-infection in Covid-19 patients","author":"Toombs","year":"2020","journal-title":"J Med Virol."},{"key":"10.1016\/j.semerg.2021.06.005_bib0675","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jmii.2020.05.013","article-title":"Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?","volume":"53","author":"Lai","year":"2020","journal-title":"J Microbiol Immun Infect"},{"key":"10.1016\/j.semerg.2021.06.005_bib0680","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/vaccines8030471","article-title":"The association between influenza and pneumococcal vaccinations and SARS-CoV-2 infection: Data from the EPICOVID19. Web-based survey","volume":"8","author":"Noale","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.semerg.2021.06.005_bib0685","doi-asserted-by":"crossref","first-page":"e2000076","DOI":"10.1002\/bies.202000076","article-title":"Age and location in severity of COVID-19 pathology: Do lactoferrin and pneumococcal vaccination explain low infant mortality and regional differences?","volume":"42","author":"Root-Bernstein","year":"2020","journal-title":"Bioessays."},{"key":"10.1016\/j.semerg.2021.06.005_bib0690","doi-asserted-by":"crossref","first-page":"e02347-20","DOI":"10.1128\/mBio.02347-20","article-title":"Pneumococcal conjugate vaccine protection against coronavirus-associated pneumonia hospitalization in children living with and without HIV","volume":"12","author":"Nunes","year":"2021","journal-title":"mBio."},{"key":"10.1016\/j.semerg.2021.06.005_bib0695","unstructured":"World Health Organization. Infection Prevention and control guidance for long-term care facilities in the context of COVID-19. Interim guidance [consultado Sep 2020]. Disponible en: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331508\/WHO-2019-nCoV-IPC_long_term_care-2020.1-eng.pdf?sequence=1&isAllowed=yel"},{"key":"10.1016\/j.semerg.2021.06.005_bib0700","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/docs\/CalendarioVacunacion_Todalavida.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0705","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/vacunas\/profesionales\/enfNeumococicaInvasiva.htm"},{"key":"10.1016\/j.semerg.2021.06.005_bib0710","unstructured":"Consultado 29 Mar 2021. Disponible en: http:\/\/www.codepa.es\/modulgex\/workspace\/publico\/modulos\/web\/docs\/apartados\/65\/040918_023255_3181688223.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0715","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.juntadeandalucia.es\/export\/drupaljda\/Instruccion_Neumococo_Andalucia_Julio2019.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0720","unstructured":"Comunidad de Madrid. Calendario de vacunaci\u00f3n en el adulto a\u00f1o 2019 [consultado 29 Mar 2021]. Disponible en: http:\/\/www.madrid.org\/bvirtual\/BVCM050122.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0725","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.juntadeandalucia.es\/export\/drupaljda\/instruccion_vacunacion_neumococica_pacientes_post_covid_grave_26-11-2020-F.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0730","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.sergas.es\/Saude-publica\/Vacinaci%C3%B3n-no-adulto?idioma=es"},{"key":"10.1016\/j.semerg.2021.06.005_bib0735","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.riojasalud.es\/files\/content\/salud-publica-consumo\/epidemiologia\/vacunaciones\/VACUNACION_ANTINEUMOCOCICA_Residencias_Personas_mayores_2020-2021.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0740","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.saludcastillayleon.es\/profesionales\/es\/vacunaciones\/calendario-vacunal-toda-vida\/"},{"key":"10.1016\/j.semerg.2021.06.005_bib0745","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.juntadeandalucia.es\/export\/drupaljda\/instruccion_vacunacion_neumococica_60-69an%CC%83os_26-11-2020-F.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0750","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.castillalamancha.es\/sites\/default\/files\/documentos\/pdf\/20160309\/calendario_vacunal_adultos.pdf"},{"journal-title":"Nota informativa sobre a vacunaci\u00f3n antineumoc\u00f3cica conxugada en pacientes en residencias da terceira idade setembro","year":"2020","author":"Xunta de Galicia","key":"10.1016\/j.semerg.2021.06.005_bib0755"},{"key":"10.1016\/j.semerg.2021.06.005_bib0760","unstructured":"Rioja. Campa\u00f1a de vacunaci\u00f3n antineumoc\u00f3cica conjugada en poblaci\u00f3n de Residencias de Personas Mayores de la Rioja [consultado 29 Mar 2021]. Disponible en: https:\/\/www.riojasalud.es\/f\/rs\/docs\/VACUNACION_ANTINEUMOCOCICA_Residencias_Personas_mayores_2020-2021.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0765","unstructured":"Consultado 29 Mar 2021. Disponible en: http:\/\/www.murciasalud.es\/recursos\/ficheros\/469244-Protocolo.Campana.gripe.neumo.2020-21.20201026.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0770","unstructured":"Consultado 29 Mar 2021. Disponible en: http:\/\/www.caib.es\/sites\/vacunacions\/f\/338658;1"},{"key":"10.1016\/j.semerg.2021.06.005_bib0775","first-page":"1069","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u2265 65 years","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR."},{"key":"10.1016\/j.semerg.2021.06.005_bib0780","article-title":"Nationwide trends of invasive pneumococcal disease in spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","author":"De Miguel","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0785","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2807\/1560-7917.ES.2018.23.16.17-00454","article-title":"Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): Results from the Burden of Communicable Diseases in Europe study European Union and European Economic Area countries, 2009 to 2013","volume":"23","author":"Cassini","year":"2018","journal-title":"Eurosurveillance."},{"key":"10.1016\/j.semerg.2021.06.005_bib0790","unstructured":"Informes de Vigilancia de la Gripe en Espa\u00f1a. Instituto de Salud Carlos III. Sistema de Vigilancia de la Gripe en Espa\u00f1a. Disponible en: https:\/\/vgripe.isciii.es\/documentos\/20192020\/InformesAnuales\/Informe_Vigilancia_GRIPE_2019-2020_03092020.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0795","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/gripometro.es\/"},{"key":"10.1016\/j.semerg.2021.06.005_bib0800","article-title":"Lethal synergism between influenza and Streptococcus pneumoniae","volume":"2","author":"Rudd","year":"2016","journal-title":"J Infect Pulm Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0805","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1702090","article-title":"Acute myocardial infarction after laboratory-confirmed influenza infection","volume":"378","author":"Kwong","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.06.005_bib0810","doi-asserted-by":"crossref","first-page":"31386","DOI":"10.1073\/pnas.2012265117","article-title":"Capillary leakage provides nutrients and antioxidants for rapid pneumococcal proliferation in influenza-infected lower airways","volume":"117","author":"Sender","year":"2020","journal-title":"Proc Natl Acad Sci."},{"key":"10.1016\/j.semerg.2021.06.005_bib0815","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2730","article-title":"Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza","author":"Merkler","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.semerg.2021.06.005_bib0820","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJMra1808137","article-title":"Acute infection and myocardial infarction","volume":"380","author":"Musher","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.06.005_bib0825","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/jmv.25953","article-title":"Coinfection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus\/enterovirus?","volume":"92","author":"Nowak","year":"2020","journal-title":"J Med Virol."},{"key":"10.1016\/j.semerg.2021.06.005_bib0830","first-page":"2020","article-title":"Influenza vaccination and COVID19 mortality in the USA","volume":"26","author":"Zanettini","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.semerg.2021.06.005_bib0835","article-title":"Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil","author":"Fink","year":"2020","journal-title":"BMJ Evid Based Med."},{"key":"10.1016\/j.semerg.2021.06.005_bib0840","article-title":"Interactions between SARS-CoV-2 and influenza and the impact of coinfection on disease severity: a test negative design","author":"Stowe","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.semerg.2021.06.005_bib0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2020.05.070","article-title":"Influenza vaccination as a novel means of preventing coronary heart disease: Effectiveness in older adults","author":"Aidoud","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.semerg.2021.06.005_bib0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-020-01836-z","article-title":"Influenza vaccination and risk for cardiovascular events: A nationwide self-controlled case series study","volume":"21","author":"Sen","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.semerg.2021.06.005_bib0855","unstructured":"Seasonal influenza vaccination in Europe \u2014 Vaccination recommendations and coverage rates for eight influenza seasons (2007-2008 to 2014-2015). European Centre for Disease Prevention and Control (ECDC). Stockholm, 2017 [consultado 29 Mar 2021]. Disponible en: https:\/\/ecdc.europa.eu\/en\/publications-data\/seasonal-influenza-vaccination-europe-vaccination-recommendations-and-coverage-2007-2015#no-link"},{"key":"10.1016\/j.semerg.2021.06.005_bib0860","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2020\/Ausgaben\/32-33_20.pdf?__blob=publicationFile;1"},{"key":"10.1016\/j.semerg.2021.06.005_bib0865","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2016.1182275","article-title":"Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain","volume":"12","author":"Garcia","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.semerg.2021.06.005_bib0870","unstructured":"CIMA. Buscador para profesionales sanitarios [consultado 29 Mar 2021. Disponible en: https:\/\/www.aemps.gob.es\/cima\/publico\/buscadoravanzado.html"},{"key":"10.1016\/j.semerg.2021.06.005_bib0875","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14760584.2014.852476","article-title":"Influenza vaccines: From whole virus preparations to recombinant protein technology","volume":"13","author":"Huber","year":"2014","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.semerg.2021.06.005_bib0880","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eimc.2015.06.011","article-title":"[Influenza vaccination Effectiveness of current vaccines and future challenges]","volume":"33","author":"Ortiz de Lejarazu","year":"2015","journal-title":"Enferm Infec Microbiol Clin."},{"key":"10.1016\/j.semerg.2021.06.005_bib0885","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","article-title":"Current and next generation influenza vaccines: Formulation and production strategies","volume":"94","author":"Soema","year":"2015","journal-title":"Eur J Pharm Biopharm."},{"key":"10.1016\/j.semerg.2021.06.005_bib0890","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4065\/mcp.2009.0615","article-title":"Influenza vaccines: From surveillance through production to protection","volume":"85","author":"Tosh","year":"2010","journal-title":"Mayo Clinic Proc."},{"key":"10.1016\/j.semerg.2021.06.005_bib0895","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.semerg.2021.06.005_bib0900","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1080\/21645515.2018.1460297","article-title":"Cell culture-derived flu vaccine: Present and future","volume":"14","author":"Perez-Rubio","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.semerg.2021.06.005_bib0905","unstructured":"Consultado 29 Mar 2021. Disponible en: http:\/\/publications.gc.ca\/collections\/collection_2018\/aspc-phac\/HP40-210-2018-eng.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0910","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/seasonal-influenza-vaccines-systematic-review-efficacy.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0915","doi-asserted-by":"crossref","first-page":"226","DOI":"10.37201\/req\/043.2020","article-title":"Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad [High-dose trivalent influenza vaccine. Efficacy and effectiveness]","volume":"33","author":"Gil de Miguel","year":"2020","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.semerg.2021.06.005_bib0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.37201\/req\/110.2020","article-title":"Vacuna antigripal trivalente de alta dosis: seguridad e inmunogenicidad [High-dose trivalent influenza vaccine: Safety and immunogenicity]","volume":"34","author":"Ortiz de Lejarazu","year":"2021","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.semerg.2021.06.005_bib0925","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1473-3099(15)00249-2","article-title":"Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: An economic evaluation of data from a randomised controlled trial","volume":"15","author":"Chit","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0930","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1080\/21645515.2016.1215395","article-title":"High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors","volume":"12","author":"Becker","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.semerg.2021.06.005_bib0935","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jamda.2018.12.003","article-title":"Cost benefit of high-dose vs standard-dose influenza vaccine in a long-term care population during an A\/H1N1-predominant influenza season","volume":"20","author":"Shireman","year":"2019","journal-title":"J Am Med Dir Assoc."},{"key":"10.1016\/j.semerg.2021.06.005_bib0940","article-title":"Economic assessment of a high-dose versus standard-dose influenza vaccine: Estimating the impact on hospitalization cost for cardio-respiratory disease in the US veteran population","author":"Van Aalst","year":"2019","journal-title":"Paper presented at: ISPOR; 18-22 May"},{"key":"10.1016\/j.semerg.2021.06.005_bib0945","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.vaccine.2014.10.079","article-title":"Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors","volume":"33","author":"Chit","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.semerg.2021.06.005_bib0950","article-title":"An economic model to estimate the cost-effectiveness of trivalent influenza vaccine high dose for the elderly population in England and Wales","author":"Skinner","year":"2018","journal-title":"Paper presented at: International Society for Pharmacoeconomics Outcomes Research (ISPOR) 21st Annual European Conference; November 10-14"},{"key":"10.1016\/j.semerg.2021.06.005_bib0955","article-title":"An economic model to estimate the public health impact and cost-effectiveness of vaccination of seniors with Fluzone high dose influenza vaccine in Australia","author":"Largeron","year":"2018","journal-title":"Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 8th Asia Pacific Conference; September 8-11"},{"key":"10.1016\/j.semerg.2021.06.005_bib0960","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jgs.14323","article-title":"Cost-effectiveness and public health effect of influenza vaccine strategies for US elderly adults","volume":"64","author":"Raviotta","year":"2016","journal-title":"J Am Geriatr Soc."},{"journal-title":"A dynamic transmission model to estimate the public health impact and cost-effectiveness of trivalent influenza vaccine high dose for the elderly population in England and Wales","year":"2018","author":"Cr\u00e9pey","key":"10.1016\/j.semerg.2021.06.005_bib0965"},{"key":"10.1016\/j.semerg.2021.06.005_bib0970","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/supemtek-epar-product-information_en.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib0975","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1714916","article-title":"Chasing seasonal influenza \u2014 The need for a universal influenza vaccine","volume":"378","author":"Paules","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.06.005_bib0980","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/21645515.2020.1738168","article-title":"Pertussis in high-risk groups: An overview of the past quarte-century","volume":"16","author":"Jenkins","year":"2020","journal-title":"Hum Vaccin Immunother."},{"article-title":"Pertussis","year":"2020","series-title":"ECDC Annual Epidemiological Report for 2018","key":"10.1016\/j.semerg.2021.06.005_bib0985"},{"key":"10.1016\/j.semerg.2021.06.005_bib0990","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10096-017-3158-6","article-title":"Long-lasting cough in an adult German population: Incidence, symptoms, and related pathogens","volume":"37","author":"Weinberger","year":"2018","journal-title":"Eur J Clin Microbiol Infec Dis."},{"key":"10.1016\/j.semerg.2021.06.005_bib0995","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/14760584.2019.1588727","article-title":"The burden of pertussis in older adults: What is the role of vaccination? Asystematic literatura review","volume":"18","author":"Kandeil","year":"2019","journal-title":"Exp Rev Vaccines."},{"key":"10.1016\/j.semerg.2021.06.005_bib1000","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eimc.2012.12.011","article-title":"Tos ferina en Espa\u00f1a. Situaci\u00f3n epidemiol\u00f3gica y estrategias de prevenci\u00f3n y control. Recomendaciones del Grupo de Trabajo de Tos ferina","volume":"31","author":"Campins","year":"2013","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.semerg.2021.06.005_bib1005","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eimc.2015.02.001","article-title":"Vacuna de la tos ferina. Reemergencia de la enfermedad y nuevas estrategias de vacunaci\u00f3n","volume":"33","author":"Moraga","year":"2015","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.semerg.2021.06.005_bib1010","unstructured":"Consultado 29 Mar 2021. Disponible en: https:\/\/goldcopd.org\/wp-content\/uploads\/2020\/12\/GOLD-2021-POCKET-GUIDE-v2.0-14Dec20_WMV.pdf"},{"key":"10.1016\/j.semerg.2021.06.005_bib1015","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15585\/mmwr.mm6937a6","article-title":"Decreased influenza activity during the COVID-19 pandemic \u2014 United States, Australia Chile, and South Africa, 2020","volume":"69","author":"Olsen","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.semerg.2021.06.005_bib1020","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.2020.6173","article-title":"Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan","volume":"323","author":"Sakamoto","year":"2020","journal-title":"JAMA."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321001805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321001805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:41:35Z","timestamp":1761108095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359321001805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1138359321001805"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2021.06.005","relation":{},"ISSN":["1138-3593"],"issn-type":[{"type":"print","value":"1138-3593"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vacunaci\u00f3n frente a la neumon\u00eda adquirida en la comunidad del adulto. Actualizaci\u00f3n 2021 del posicionamiento del Grupo de Neumoexpertos en Prevenci\u00f3n","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}